BRCA mutation

Our findings indicate that CXCL14 serves as a promising independent prognostic factor associated with an anti-tumor immune microenvironment in BRCA, with ECs identified as a major source. Furthermore, TP53 mutations may promote BRCA progression by repressing endothelial through CXCL14 transcription.

Radiomics, which involves extracting high-dimensional features from medical images, has shown promise in differentiating between benign and malignant tumors, predicting genetic mutations (e.g., BRCA), and assessing tumor heterogeneity. Artificial intelligence (AI) models, particularly deep learning (DL) algorithms, have demonstrated high accuracy in diagnosing OC and predicting patient outcomes, often outperforming traditional methods.

Animal experiment further confirmed that downregulating THUMPD3-AS1 enhanced olaparib sensitivity to hinder the in vivo growth of OC cells through inhibiting PI3K/AKT/mTOR pathway. Our research revealed THUMPD3-AS1 as a promising target for OC therapy.

P3, N=663, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2028 --> Dec 2027 | Trial primary completion date: May 2028 --> Dec 2027

We identified BRCA gene mutations in 38.6% of our patients. Most comparisons revealed no significant differences between BRCA-positive and BRCA-negative patients, highlighting the need for additional studies to determine the prognostic and clinical value of gene testing in EOC.

We also address challenges confronting clinical translation: on-target toxicities, resistance mechanisms, spatial heterogeneity in ferroptosis susceptibility, and the need for validated predictive biomarkers. By synthesizing these cutting-edge findings, we provide a framework that integrates cancer genetics, microenvironment metabolism, and immunology, distinguishing this review from previous summaries and highlighting actionable vulnerabilities for overcoming chemoresistance in ovarian cancer.

P2, N=30, Not yet recruiting, Stuthi Perimbeti

P2, N=80, Recruiting, MacroGenics | N=60 --> 80 | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Feb 2027 --> Jul 2027

P=N/A, N=320, Completed, Georgetown University | N=560 --> 320 | Trial completion date: Dec 2026 --> Apr 2026 | Active, not recruiting --> Completed

Pathologic complete response was higher in the mBRCA group than in the wt/unknown BRCA group (74.0% vs 61.7%). With a median follow-up of 22 months, event-free and overall survival were favorable in both groups, with a non-significant trend toward improved event-free survival in the mBRCA group, particularly among patients with residual disease.

ERGs-based prognostic signatures could distinguish clinical outcomes of BRCA patients and were correlated with immune regulation and mutation patterns. The ERGs-constructed risk scoring system and molecular subtypes have the potential to serve as preclinical biological and immunological markers, paving the way for clinical management and treatment of BRCA.

In this article, we detail emerging therapeutic strategies for synthetic lethal drug development and discuss promising therapeutic strategies targeting such interactions. These include MTA-cooperative PRMT5 inhibitors and MAT2A inhibitors in MTAP-deficient cancers, WRN inhibitors in microsatellite instablility-high tumors, as well as PKMYT1 inhibitors and WEE1 inhibitors in CCNE1-amplified tumors.